STEMI TREATMENT BY CRP REMOVAL PROMISES CLINICAL BENEFIT: FIRST RESULTS OF THE CAMI1 STUDY

Inflammation is recognized as an important pathogenic feature in CV disease. In patients with STEMI, C-reactive protein (CRP) is a marker of poor prognosis and independently predicts 30-d mortality. In STEMI, CRP may be involved in myocardial damage by activating the complement system in the